Filing Flows › Biocryst Pharmaceuticals (BCRX) › R&D spending
Biocryst Pharmaceuticals (BCRX) R&D spending by quarter
Biocryst Pharmaceuticals' R&D spending was $58.2M in Q3 2026 (third quarter 2026), +12% from Q2 2026. Over the last 7 quarters it ranged from $37.3M (Q1 2025) to $60.3M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $58.2M | +12% | +31% |
| Q2 2026 | $52.0M | -14% | +20% |
| Q1 2026 | $60.3M | +48% | +62% |
| Q4 2025 | $40.9M | -8% | — |
| Q3 2025 | $44.6M | +3% | — |
| Q2 2025 | $43.4M | +16% | — |
| Q1 2025 | $37.3M | — | — |
Q3 2026 at a glance
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biocryst Pharmaceuticals' R&D spending?
Biocryst Pharmaceuticals' R&D spending was $58.2M in Q3 2026 (third quarter 2026), +12% from Q2 2026.
How has Biocryst Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $37.3M (Q1 2025) to $60.3M (Q1 2026).
Q3 2026 results → · How Biocryst Pharmaceuticals makes money →